Utilizing a “two-hit” mouse model, we demonstrated that pharmacological blockade and in vivo knockdown of ARG2 enhanced T cell immune responses against secondary infections by restoring CD4+ T cells, reducing bacterial loads and improving survival rates. Here, CD4 is linked to infection.